RecruitingPhase 3NCT03966170
Citicoline as Neuroprotector in Preterm
Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial
Sponsor
Sherief Abd-Elsalam
Enrollment
40 participants
Start Date
May 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
Citicoline as neuroprotector in preterm
Eligibility
Max Age: 1 Month
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Citicoline and a drug called Placebo oral tablet for people with pre-term. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 1 Month.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCiticoline
Citicoline as neuroprotector
DRUGPlacebo oral tablet
placebo drug
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03966170
Related Trials
Improving Preterm Kidney Outcomes With Caffeine
NCT072620601 location
Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates
NCT072160531 location
Admission to Kangaroo Mother Care (KMC) Ward and Maternal Postpartum Depression
NCT065457601 location
Motor-voice Assessment in Infants (MAMI)
NCT068072031 location
Cerebral Oxygen Saturation Monitoring During Optimum Cord Management in Preterm Infants
NCT065260911 location